An exploratory model can identify patterns worth investigating without demonstrating a treatment benefit. This distinction is central to the 2026 tesamorelin pilot. Primary study
Study and results
Twenty-two adults with cognition ranging from normal to mild impairment were assessed in a double-blind, placebo-controlled ten-week trial. Direct groupwise analyses did not link treatment to significant changes in the reported study measures. Exploratory machine-learning analyses identified possible treatment-related brain patterns. Registration: NCT02553603. Primary report
Our appraisal: prediction is not treatment efficacy
A model that distinguishes treatment groups may capture a biological signal, baseline imbalance, measurement artifact, or overfitting. Its classification performance is not a direct estimate of improvement in cognition. The prediction target must be stated clearly.
Small datasets with many imaging features are particularly sensitive to analysis choices. Feature selection, tuning, preprocessing, and validation need to be separated appropriately. If information from a test set influences model development, apparent performance can be optimistic.
Exploratory findings are useful when presented as hypotheses for independent testing. They should not replace the direct trial results simply because the conventional analysis was not significant. Nor does a null small trial prove the intervention has no possible effect; it leaves uncertainty that should be described rather than resolved through a more favorable analysis label.
Brain connectivity and morphometry are not interchangeable with everyday cognitive function or prevention of dementia. A clinical claim requires patient-relevant outcomes and sufficient follow-up.
Before release, inspect the analysis plan, training and validation procedure, missing imaging data, and the relationship between model-derived features and actual cognitive change. This study supports further methodological and mechanistic investigation, not established cognitive enhancement or dementia prevention with tesamorelin.
Frequently asked questions
Was the study large?
No; it assessed 22 participants.
Did direct groupwise measures show significant treatment changes?
The report did not identify them.
Were exploratory machine-learning patterns reported?
Yes.
Does classifying treatment assignment prove cognitive benefit?
No.
Why is independent validation important?
It helps distinguish reproducible signal from overfitting.
Does an imaging pattern establish dementia prevention?
No.
What should the headline preserve?
The null direct comparisons and exploratory status of the model findings.